Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARWR 
Arrowhead Pharmaceuticals Inc (ARWR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ARWR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $44
1 Year Target Price $44
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.45% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.60B USD | Price to earnings Ratio - | 1Y Target Price 44 |
Price to earnings Ratio - | 1Y Target Price 44 | ||
Volume (30-day avg) 15 | Beta 0.95 | 52 Weeks Range 9.57 - 30.41 | Updated Date 07/10/2025 |
52 Weeks Range 9.57 - 30.41 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.41% | Operating Margin (TTM) 70.24% |
Management Effectiveness
Return on Assets (TTM) -5.86% | Return on Equity (TTM) -26.22% |
Valuation
Trailing PE - | Forward PE 111.11 | Enterprise Value 1898165212 | Price to Sales(TTM) 4.78 |
Enterprise Value 1898165212 | Price to Sales(TTM) 4.78 | ||
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA -11.02 | Shares Outstanding 138100000 | Shares Floating 120895883 |
Shares Outstanding 138100000 | Shares Floating 120895883 | ||
Percent Insiders 13.02 | Percent Institutions 77.19 |
Upturn AI SWOT
Arrowhead Pharmaceuticals Inc
Company Overview
History and Background
Arrowhead Pharmaceuticals Inc. was founded in 1989 as a gene therapy company. Initially focused on broader gene delivery, it shifted its focus to RNA interference (RNAi) based therapeutics around 2011, becoming a leader in this field. Key milestones include the development of its TRiMu2122 platform and advancing multiple RNAi therapeutics into clinical trials.
Core Business Areas
- RNAi Therapeutics Development: Focuses on discovering and developing RNAi-based drugs targeting a wide range of diseases, primarily liver-related, cardiovascular and pulmonary diseases. Their TRiM platform is key.
- Licensing and Collaboration: Partners with pharmaceutical companies to develop and commercialize RNAi therapeutics, generating revenue through licensing agreements and milestone payments.
Leadership and Structure
Arrowhead is led by President and CEO Christopher Anzalone. The company has a typical organizational structure for a biotech firm, including research and development, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- ARO-APOC3: An RNAi therapeutic targeting APOC3 to treat hypertriglyceridemia. It's in late-stage clinical trials. Competitors include antisense oligonucleotide drugs such as olezarsen (Ionis/Roche), gene therapies like bempedoic acid (Esperion) and other triglyceride-lowering drugs.
- Market Share Data: Market share information is premature as product is still in development/clinical stages. Competitors include other drug developers for similar cardiovascular indications. No market share for ARO-APOC3 yet.
- ARO-ANG3: An RNAi therapeutic targeting ANGPTL3 to treat dyslipidemia. It's in late-stage clinical trials. Competitors include evinacumab (Regeneron), gene therapies and other lipid-lowering drugs.
- Market Share Data: Market share information is premature as product is still in development/clinical stages. Competitors include other drug developers for similar cardiovascular indications. No market share for ARO-ANG3 yet.
- ARO-HSD: An RNAi therapeutic targeting HSD17B13 to treat liver diseases. In clinical trials. Competitors: other liver disease treatment developers.
- Market Share Data: Market share information is premature as product is still in development/clinical stages. Competitors include other drug developers for similar indications. No market share for ARO-HSD yet.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in novel therapeutics like RNAi, is highly competitive, innovative, and regulated. It is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The market is increasingly focusing on precision medicine and targeted therapies.
Positioning
Arrowhead is a leader in RNAi therapeutics, particularly with its TRiMu2122 platform, enabling targeted delivery of RNAi to specific tissues. Its competitive advantage lies in its proprietary technology and clinical pipeline. Its platform offers good specificity and strong therapeutic efficacy.
Total Addressable Market (TAM)
The TAM for RNAi therapeutics is substantial and growing, estimated to reach tens of billions of dollars across various indications like cardiovascular diseases, liver diseases, and cancer. Arrowhead is positioned to capture a significant portion of this market with its strong platform and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary TRiMu2122 platform technology for RNAi delivery
- Strong clinical pipeline with multiple programs in late-stage development
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single technology platform (TRiMu2122)
- High R&D costs and long development timelines inherent to biotech
- Dependence on partnerships for revenue generation and commercialization
- Clinical trial risks and regulatory uncertainties
- Negative earnings and cash flow
Opportunities
- Expanding pipeline into new therapeutic areas
- Securing regulatory approvals for lead programs
- Entering new partnerships and collaborations
- Acquiring complementary technologies or companies
- Growing market demand for targeted therapies
Threats
- Competition from other RNAi therapeutics and alternative technologies
- Clinical trial failures or setbacks
- Regulatory hurdles and delays
- Patent challenges or invalidation
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- REGN
- VRTX
Competitive Landscape
Arrowhead has a strong position in the RNAi therapeutics space due to its proprietary TRiMu2122 platform. However, it faces competition from companies with alternative RNAi technologies (Alnylam) and other therapeutic modalities (Ionis, Regeneron, Vertex). The competitive landscape is constantly evolving with new innovations and emerging players.
Growth Trajectory and Initiatives
Historical Growth: Arrowhead's historical growth has been driven by advancements in its TRiMu2122 platform and progress in its clinical pipeline. Share price has fluctuated widely based on clinical trial outcomes and partnership deals.
Future Projections: Analysts project significant growth in revenue as lead programs advance toward potential regulatory approval and commercialization. Future growth is highly dependent on clinical trial success and expansion of the pipeline.
Recent Initiatives: Recent initiatives include advancing lead programs ARO-APOC3, ARO-ANG3, and ARO-HSD into late-stage clinical trials, expanding collaborations with pharmaceutical companies, and investing in research and development of new RNAi therapeutics.
Summary
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics with a strong technology platform and promising clinical pipeline. Its success is highly dependent on the outcome of its clinical trials and partnerships. While financially stable, the company has not made profits yet, and faces competition from others. Securing regulatory approvals is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Company Website, Analyst Reports, Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arrowhead Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 1993-06-16 | Chairman, CEO & President Dr. Christopher R. Anzalone Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 609 | Website https://arrowheadpharma.com |
Full time employees 609 | Website https://arrowheadpharma.com | ||
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.